एप्रेपिटेंट और ट्रैबेक्टेडिन का इंटरैक्शन

CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors ( 7.1 )

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 )

Table 5: Drug Interactions with EVDI Strong CYP3A Inhibitors Prevention or Management Avoid concomitant use of strong CYP3A inhibitors in patients taking EVDI.

If concomitant use of a strong CYP3A inhibitor for short-term use (i.e., less than 14 days) cannot be avoided, administer the strong CYP3A inhibitor 1 week after the EVDI infusion, and discontinue it the day prior to the next EVDI infusion Mechanism and Clinical Effect(s) Concomitant administration of trabectedin with ketoconazole, a strong CYP3A inhibitor, increased…

Strong CYP3A Inducers Prevention or Management Avoid concomitant use of strong CYP3A inducers in patients taking EVDI.